Marketdash
Back to News

Medtronic's MiniMed Diabetes Unit Files for IPO After 24 Years

MarketDash Editorial Team
6 hours ago
Medtronic's diabetes division MiniMed Group has filed for a U.S. IPO as the medical device giant prepares to spin off the business it acquired for $3.3 billion in 2001. The company will list on Nasdaq under the ticker MMED, with Medtronic retaining majority voting control initially.

Medtronic (MDT) is sending its diabetes business out into the world. MiniMed Group, the Northridge, California-based unit that makes insulin delivery devices and glucose monitors, filed paperwork Friday for a U.S. initial public offering as part of its separation from the medical device giant.

The numbers tell a story of steady growth with room for improvement. For the six months ended October 24, MiniMed posted net sales of $1.48 billion, up from $1.3 billion in the same period a year earlier, according to the SEC filing. The company's net loss narrowed to $21 million from $23 million, showing progress toward profitability as it prepares to stand on its own.

From Acquisition to Independence

Medtronic acquired MiniMed in 2001 for roughly $3.3 billion, and the unit has spent more than two decades operating under the parent company's umbrella. In May, Medtronic announced plans to spin off the diabetes business through an IPO, and now that process is officially underway.

"We are proud and grateful for our Medtronic chapter. It allowed us to build deep expertise, scale globally, and improve the lives of millions of people across more than 80 countries," CEO Que Dallara wrote in a letter included in Friday's SEC filing.

The IPO proceeds will serve a couple of purposes. MiniMed plans to use part of the money to repay intercompany debt owed to Medtronic, with the rest earmarked for general corporate purposes. Think of it as settling up before moving out of the family home.

The Ownership Structure

Here's where it gets interesting. Once the IPO closes, Medtronic will still own at least 80.1% of MiniMed's voting stock. This isn't a clean break right away. The plan is for Medtronic to eventually distribute all or part of its stake to Medtronic shareholders through either a spin-off or split-off transaction. So current Medtronic investors will likely end up with MiniMed shares down the road.

MiniMed has tapped the heavy hitters to lead the offering: Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are serving as lead underwriters. The company plans to list on the Nasdaq under the ticker symbol "MMED."

IPO Market Heating Up

The timing is notable. After a rough start to 2025—marked by uncertainty around tariffs, stock market volatility, and a government shutdown that briefly halted trading—IPO activity appears to be finding its footing again.

This week provided a strong signal. Medical supply giant Medline (MDLN) soared over 40% in its Nasdaq debut, raising $6.26 billion in the largest IPO of the year globally. That's the kind of reception that gives other companies considering public offerings some confidence.

Earlier this month, New York Stock Exchange President Lynn Martin said 2026 is shaping up to be a breakout year for public offerings, with January and the first quarter expected to be especially active. If MiniMed's deal goes smoothly, it could help set the tone for what market watchers hope will be a busy stretch for new listings.

Back to News

Medtronic's MiniMed Diabetes Unit Files for IPO After 24 Years

MarketDash Editorial Team
6 hours ago
Medtronic's diabetes division MiniMed Group has filed for a U.S. IPO as the medical device giant prepares to spin off the business it acquired for $3.3 billion in 2001. The company will list on Nasdaq under the ticker MMED, with Medtronic retaining majority voting control initially.

Medtronic (MDT) is sending its diabetes business out into the world. MiniMed Group, the Northridge, California-based unit that makes insulin delivery devices and glucose monitors, filed paperwork Friday for a U.S. initial public offering as part of its separation from the medical device giant.

The numbers tell a story of steady growth with room for improvement. For the six months ended October 24, MiniMed posted net sales of $1.48 billion, up from $1.3 billion in the same period a year earlier, according to the SEC filing. The company's net loss narrowed to $21 million from $23 million, showing progress toward profitability as it prepares to stand on its own.

From Acquisition to Independence

Medtronic acquired MiniMed in 2001 for roughly $3.3 billion, and the unit has spent more than two decades operating under the parent company's umbrella. In May, Medtronic announced plans to spin off the diabetes business through an IPO, and now that process is officially underway.

"We are proud and grateful for our Medtronic chapter. It allowed us to build deep expertise, scale globally, and improve the lives of millions of people across more than 80 countries," CEO Que Dallara wrote in a letter included in Friday's SEC filing.

The IPO proceeds will serve a couple of purposes. MiniMed plans to use part of the money to repay intercompany debt owed to Medtronic, with the rest earmarked for general corporate purposes. Think of it as settling up before moving out of the family home.

The Ownership Structure

Here's where it gets interesting. Once the IPO closes, Medtronic will still own at least 80.1% of MiniMed's voting stock. This isn't a clean break right away. The plan is for Medtronic to eventually distribute all or part of its stake to Medtronic shareholders through either a spin-off or split-off transaction. So current Medtronic investors will likely end up with MiniMed shares down the road.

MiniMed has tapped the heavy hitters to lead the offering: Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley are serving as lead underwriters. The company plans to list on the Nasdaq under the ticker symbol "MMED."

IPO Market Heating Up

The timing is notable. After a rough start to 2025—marked by uncertainty around tariffs, stock market volatility, and a government shutdown that briefly halted trading—IPO activity appears to be finding its footing again.

This week provided a strong signal. Medical supply giant Medline (MDLN) soared over 40% in its Nasdaq debut, raising $6.26 billion in the largest IPO of the year globally. That's the kind of reception that gives other companies considering public offerings some confidence.

Earlier this month, New York Stock Exchange President Lynn Martin said 2026 is shaping up to be a breakout year for public offerings, with January and the first quarter expected to be especially active. If MiniMed's deal goes smoothly, it could help set the tone for what market watchers hope will be a busy stretch for new listings.